II期临床-话题@MedSci

#II期临床#

478篇内容 | 2588人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1524807, encodeId=2c74152480eb8, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, objectType=article, longId=193802, objectId=898d1938022e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898d1938022e, replyNumber=0, likeNumber=57, createdTime=2020-05-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898d1938022e, moduleTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898d1938022e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524806, encodeId=7cc115248063e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, objectType=article, longId=193525, objectId=9a4819352542, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a4819352542, replyNumber=0, likeNumber=72, createdTime=2020-05-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a4819352542, moduleTitle=AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a4819352542)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524805, encodeId=877815248058e, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, objectType=article, longId=193524, objectId=6f49193524a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f49193524a1, replyNumber=0, likeNumber=46, createdTime=2020-05-06, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f49193524a1, moduleTitle=女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f49193524a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524804, encodeId=8c191524804ea, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, objectType=article, longId=193386, objectId=63df19338615, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63df19338615, replyNumber=0, likeNumber=52, createdTime=2020-05-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63df19338615, moduleTitle=获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63df19338615)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524803, encodeId=3ca0152480385, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, objectType=article, longId=193204, objectId=9f0e19320472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f0e19320472, replyNumber=0, likeNumber=90, createdTime=2020-05-01, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f0e19320472, moduleTitle=瑞德西韦治疗重症住院COVID-19患者III期临床数据公开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f0e19320472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524802, encodeId=7f0c1524802e4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=193035, objectId=ed7619303569, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed7619303569, replyNumber=0, likeNumber=61, createdTime=2020-04-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed7619303569, moduleTitle=Merimepodib治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed7619303569)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524801, encodeId=a9c115248017b, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, objectType=article, longId=193033, objectId=b12819303320, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12819303320, replyNumber=0, likeNumber=62, createdTime=2020-04-28, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12819303320, moduleTitle=II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12819303320)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524800, encodeId=cd5515248001f, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, objectType=article, longId=192743, objectId=597a192e43e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597a192e43e8, replyNumber=0, likeNumber=63, createdTime=2020-04-24, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597a192e43e8, moduleTitle=Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597a192e43e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524799, encodeId=08671524e99f4, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, objectType=article, longId=192391, objectId=50af192391d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50af192391d8, replyNumber=0, likeNumber=58, createdTime=2020-04-18, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50af192391d8, moduleTitle=Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50af192391d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524798, encodeId=4a191524e98e5, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=60, createdTime=2020-04-13, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524797, encodeId=5dcd1524e973d, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, objectType=article, longId=191868, objectId=b01e191868d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b01e191868d2, replyNumber=0, likeNumber=37, createdTime=2020-04-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b01e191868d2, moduleTitle=OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b01e191868d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524796, encodeId=ab031524e9624, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, objectType=article, longId=191730, objectId=1f9c191e301a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f9c191e301a, replyNumber=0, likeNumber=13, createdTime=2020-04-10, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f9c191e301a, moduleTitle=亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f9c191e301a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524795, encodeId=21a01524e9540, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, objectType=article, longId=191301, objectId=64bf1913012b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64bf1913012b, replyNumber=0, likeNumber=71, createdTime=2020-04-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64bf1913012b, moduleTitle=ONC201治疗胶质瘤的I / II期临床研究即将在日本开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64bf1913012b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524794, encodeId=e11c1524e9456, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, objectType=article, longId=191296, objectId=4009191296a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4009191296a0, replyNumber=0, likeNumber=69, createdTime=2020-04-04, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4009191296a0, moduleTitle=重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4009191296a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524793, encodeId=9b051524e93b9, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, objectType=article, longId=190723, objectId=c191190e23e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c191190e23e2, replyNumber=0, likeNumber=159, createdTime=2020-03-26, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c191190e23e2, moduleTitle=FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c191190e23e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524792, encodeId=7fdc1524e92f1, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, objectType=article, longId=190693, objectId=7c61190693ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c61190693ac, replyNumber=0, likeNumber=68, createdTime=2020-03-25, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c61190693ac, moduleTitle=抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c61190693ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524791, encodeId=6fbf1524e9127, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, objectType=article, longId=190431, objectId=604619043165, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=604619043165, replyNumber=0, likeNumber=55, createdTime=2020-03-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=604619043165, moduleTitle=20价肺炎球菌结合疫苗（20vPnC）的III期临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=604619043165)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524790, encodeId=19161524e9023, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, objectType=article, longId=190422, objectId=cfc8190422fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc8190422fa, replyNumber=0, likeNumber=62, createdTime=2020-03-21, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc8190422fa, moduleTitle=NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc8190422fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524789, encodeId=73f71524e89f6, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=Lancet：4价登革热疫苗TAK-003II期临床效果显著, objectType=article, longId=190311, objectId=8fbd190311cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fbd190311cd, replyNumber=0, likeNumber=67, createdTime=2020-03-20, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fbd190311cd, moduleTitle=Lancet：4价登革热疫苗TAK-003II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fbd190311cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1524788, encodeId=50191524e8885, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, objectTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, objectType=article, longId=189616, objectId=bc9018961683, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc9018961683, replyNumber=0, likeNumber=52, createdTime=2020-03-11, rootId=0, userName=guihongzh, userId=139811614978, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc9018961683, moduleTitle=leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc9018961683)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床

2020-05-29

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究

2020-05-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

AR-301治疗COVID-19继发性细菌感染：III期临床试验已开始

2020-05-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

女性滴虫病的治疗：Solosec®（secnidazole）的III期临床取得积极结果

2020-05-06

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

获得1亿美元融资以及FDA快速通道指定后，荣昌生物再次获得FDA批准——启动抗HER2的ADC药物治疗尿路上皮癌的II期临床试验

2020-05-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

瑞德西韦治疗重症住院COVID-19患者III期临床数据公开

2020-05-01

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Merimepodib治疗COVID-19的II期临床试验：即将开始

2020-04-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

II期临床试验测试Vafidemstat治疗重症COVID-19患者的疗效

2020-04-28

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Opdivo/Cabometyx组合疗法用于一线治疗晚期肾癌的III期临床实验成功

2020-04-24

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Leronlimab（PRO 140）治疗COVID-19的IIb / III期临床试验：首位患者入组

2020-04-18

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2020-04-13

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

OncoImmune的CD24Fc治疗新冠病毒住院患者的III期临床试验，获得FDA批准

2020-04-11

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

亚盛药业的Bcl-2抑制剂APG-2575用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的Ib/II期临床，获得NMPA的批准

2020-04-10

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

ONC201治疗胶质瘤的I / II期临床研究即将在日本开展

2020-04-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

重组人血管紧张素转化酶2治疗COVID-19的II期临床试验：即将开始

2020-04-04

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

FDA批准Actemra（tocilizumab）治疗重症COVID-19肺炎的III期临床试验

2020-03-26

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

2020-03-25

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

20价肺炎球菌结合疫苗（20vPnC）的III期临床结果

2020-03-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

NEJM:PCSK9抑制剂 InclisiranIII期临床效果显著

2020-03-21

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

Lancet：4价登革热疫苗TAK-003II期临床效果显著

2020-03-20

guihongzh (审核中...)

前往app查看评论内容

#II期临床#

leronlimab（PRO 140）治疗新冠肺炎的II期临床试验方案获得IND

2020-03-11

科室
- - 订阅+
  - 更多科室
工具
服务